Table 4: MSC therapeutics products on the market. (Data
from 2012; sources from official websites of each company, [118,119]).
Product |
Company |
Source of MSC |
Jurisdiction (Country) |
Indication |
Hearticellgram®-AMI |
FCB Pharmicell |
BM-MSC, Autologous |
MFDS (Korea) |
Acute Myocardial
Infarction |
Prochymal® |
Mesoblast |
BM-MSC, Allogeneic |
Health Canada (Canada), Medsafe (New Zealand) |
Acute GvHD |
CardioRel® |
Reliance Life
Science |
BM-MNCs &MSC, Autologous |
CDSCO (India) |
Acute Myocardial
Infarction |
Trinity Evolution® |
Orthofix |
Demineralized bone matrix with MSC, Allogeneic |
FDA (USA) |
Musculoskeletal Defects |
Allostem® |
Allosource |
Demineralized bone
matrix with adipose MSC, Allogeneic |
FDA (USA) |
Orthopedics |
Cupistem® |
Anterogen |
Adipose MSC, Autologous |
MFDS (Korea) |
Crohn’s Disease |
Cartistem® |
Medipost |
Umbilical cord
blood MSC, Allogeneic |
MFDS (Korea) |
Degenerative
Arthritis |
ReliNethra |
Reliance Life Science |
Limbal epithelial stem
cells, Autologous |
CDSCO (India) |
Eye Diseases |
Osteocel® Plus |
NuVasive |
MSC and osteoprogenitor cells, Allogeneic |
FDA (USA) |
Orthopedics |
Abbreviations: MFDS: Ministry of Food and Drug Safety;
CDSCO: Central drugs standard control organization; FDA: Food and Drug
administration